Veritas Pharma Files Cannabis Strain Patent for Opioid Analgesics

- November 28th, 2017

Veritas Pharma announced its research arm Cannevert Therapeutics filed a provisional patent application to US Patent and Trademark Office for the use of a specific cannabis strain to enhance the actions of opioid analgesics.

Veritas Pharma (CSE:VRT; OTC:VRTHF) announced its research arm Cannevert Therapeutics filed a provisional patent application to US Patent and Trademark Office for the use of a specific cannabis strain to enhance the actions of opioid analgesics.
As quoted in the press release:

Veritas CEO, Dr. Lui Franciosi stated, “We are pleased with Cannevert’s latest submission to protect its discovery of a cannabis strain that could potentially reduce the dose and side effects of clinically used opioids while maintaining a good pain relieving effect for patients.”  Dr. Franciosi goes on to say, “This strain could be also potentially useful in addressing the current fentanyl crisis throughout North America.  If we’re targeting pain or opioid addiction, we want to deliver a scientifically tested, standardized product that clinicians can rely upon.”

Click here to read the full press release.

Get the latest Cannabis Investing stock information

Get the latest information about companies associated with Cannabis Investing Delivered directly to your inbox.

Cannabis Investing

Select All
Select None

By selecting company or companies above, you are giving consent to receive email from those companies. And remember you can unsubscribe at any time

One response to “Veritas Pharma Files Cannabis Strain Patent for Opioid Analgesics

Leave a Reply

Your email address will not be published. Required fields are marked *